Sec Form 4 Filing - Laliberte Kevin @ Dova Pharmaceuticals, Inc. - 2017-11-06

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Laliberte Kevin
2. Issuer Name and Ticker or Trading Symbol
Dova Pharmaceuticals, Inc. [ DOVA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Sr. VP, Product Development
(Last) (First) (Middle)
C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245
3. Date of Earliest Transaction (MM/DD/YY)
11/06/2017
(Street)
DURHAM, NC27707
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 3.73 ( 1 ) 11/06/2017 A 24,750 ( 2 ) 03/27/2027 Common Stock 24,750 $ 0 24,750 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Laliberte Kevin
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM, NC27707
Sr. VP, Product Development
Signatures
/s/Jason Saxe, Attorney-in-Fact 11/08/2017
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The Reporting Person was granted a stock option on March 28, 2017 (the "Date of Grant") providing for milestone vesting based on the Issuer's successful completion of two Phase IIIB/IV clinical trial protocols as determined and certified in writing by the Board of Directors (the "Board"). Such milestone was achieved on September 29, 2017 and certified by the Board on November 6, 2017. The exercise price of the option is the fair market value of the Issuer's Common Stock on the Date of Grant.
( 2 )The option shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on September 29, 2018, and (ii) the balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments beginning on October 29, 2018, subject to the Person's continuous service with the Issuer as of each such date. In addition, the option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.